Mobile Evidence-Based Smoking Cessation for Veterans Living With HIV (MESH)

VA Office of Research and Development

Status and phase: Completed; Phase 4

Conditions: Human Immunodeficiency Virus; Smoking

Treatments: Behavioral: Cognitive Behavioral Therapy; Drug: Bupropion; Behavioral: Relapse Prevention Text Messaging; Drug: Varenicline; Drug: Nicotine Replacement Therapy

Study type: Interventional

Funder types: Other U.S. Federal agency

Identifiers

NCT04135937

CDX 19-002

CDA 17-005 (Other Grant/Funding Number)

Details and patient eligibility

About

Smoking is a significant cause of damage to health and quality of life specifically for Veterans with human immunodeficiency virus (HIV). Smoking cessation interventions for this population are lacking. The primary aim of this project is to explore smoking cessation treatment preferences among Veteran smokers living with HIV. The study team will refine the design and content of a smoking cessation treatment for Veteran smokers living with HIV. The intervention uses mobile health and telehealth technology to personalize smoking cessation counseling and medications and provide relapse prevention text messaging.

Full description

Although smoking is a significant cause of damage to health and quality of life specifically for Veterans with human immunodeficiency virus (HIV), smoking cessation interventions for this population are lacking. The primary aim of this project is to qualitatively explore smoking cessation treatment preferences among Veteran smokers living with HIV. The study team will refine the design and content of an intervention that uses mobile health and telehealth technology to a)individually personalize smoking cessation counseling and pharmacotherapy, and b) provide relapse prevention messaging support. It is a personalized, tailored, multi-component intervention for smoking cessation specifically designed for Veteran smokers living with HIV.

This project is highly significant given that: 1) smoking is prevalent among and particularly harmful for HIV-positive Veterans; 2) there is a dearth of research on smoking cessation for Veterans with HIV; 3) current approaches to smoking cessation in this population are not effective; 4) as the largest US provider of HIV health services, VHA is an ideal setting; and 5) the proposed intervention follows the VA Blueprint for Excellence, which prioritizes mobile health and treatment personalization to increase reach/efficacy.

Enrollment: 12 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• VHA patient
• HIV positive serostatus
• currently smoking 7 cigarettes per week
• willing to complete study procedures. Exclusion criteria are:

Exclusion criteria

• current hospitalization
• acute risk for suicide documented in the medical record
• inability to complete study procedures.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

12 participants in 1 patient group

MESH

Experimental group

Description:

Mobile Evidence-Based Smoking Cessation for Veterans Living with HIV is an intervention that is tailored for participants. It can include cognitive behavioral therapy, relapse-prevention text messaging, and/or pharmacotherapy with nicotine replacement therapy, bupropion, or varenicline.

Treatment:

Drug: Nicotine Replacement Therapy

Drug: Varenicline

Behavioral: Relapse Prevention Text Messaging

Behavioral: Cognitive Behavioral Therapy

Drug: Bupropion